Basic Information

Gene symbol S Synonyms E2 Type of gene protein-coding
Gene perturbation-related omics dataset PerturbAtlas
Description spike glycoprotein

GTO ID GTC3158
Trial ID NCT05515042
Disease COVID-19
Altered gene S
Therapeutic/Target gene Therapeutic gene
TherapymRNA vaccine
Treatment BNT162b2|COMIRNATY|Tozinameran
Co-treatment Ad26.COV2.S (VAC31518, JNJ-78436735)
Location approved UK, Bahrain, Israel, Canada, US, Rwanda, Serbia, United Arab Emirates, China, Mexico, Kuwait, Singapore, Saudi Arabia, Chile, Switzerland, EU, Ghana, Colombia, Philippines, Indonesia, Australia, Peru, South Korea, New Zealand, Japan, Brazil, Sri Lanka, Vietnam, South Africa, Thailand, Oman, Egypt, Malaysia
PhasePhase2
Recruitment statusRecruiting
TitleA Phase 2a Trial to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine Strategies in HIV-infected and HIV-uninfected Adults.
Year2022
CountrySouth Africa
Company sponsorThe Aurum Institute NPC
Other ID(s)AUR1-8-341 CEPI|DOH-27-062022-4961
Vector information
Vectoradenovirus|lipid nanoparticle

Clinical Result

Cohort1: prior vaccination with Janssen_HIV infected_Ad26.COV2.S
Administration route intramuscular injection
Dosage Ad26.COV2.S, 0.5 mL
Pts 85
Age Adult, Older_Adult
Cohort2: prior vaccination with Janssen_HV_Ad26.COV2.S
Administration route intramuscular injection
Dosage Ad26.COV2.S, 0.5 mL
Pts 15
Age Adult, Older_Adult
Cohort3: prior vaccination with Janssen_HIV infected_SARS-CoV-2 rS
Administration route intramuscular injection
Dosage SARS-CoV-2 rS, 0.5 mL
Pts 85
Age Adult, Older_Adult
Cohort4: prior vaccination with Janssen_HV_SARS-CoV-2 rS
Administration route intramuscular injection
Dosage SARS-CoV-2 rS, 0.5 mL
Pts 15
Age Adult, Older_Adult
Cohort5: prior vaccination with Janssen_HIV infected_BNT162b2
Administration route intramuscular injection
Dosage BNT162b2, 0.3 mL
Pts 85
Age Adult, Older_Adult
Cohort6: prior vaccination with Janssen_HV_BNT162b2
Administration route intramuscular injection
Dosage BNT162b2, 0.3 mL
Pts 15
Age Adult, Older_Adult
Cohort7: prior vaccination with Pfize_HIV infected_Ad26.COV2.S
Administration route intramuscular injection
Dosage Ad26.COV2.S, 0.5 mL
Pts 85
Age Adult, Older_Adult
Cohort8: prior vaccination with Pfize_HV_Ad26.COV2.S
Administration route intramuscular injection
Dosage Ad26.COV2.S, 0.5 mL
Pts 15
Age Adult, Older_Adult
Cohort9: prior vaccination with Pfize_HIV infected_SARS-CoV-2 rS
Administration route intramuscular injection
Dosage SARS-CoV-2 rS, 0.5 mL
Pts 85
Age Adult, Older_Adult
Cohort10: prior vaccination with Pfize_HV_SARS-CoV-2 rS
Administration route intramuscular injection
Dosage SARS-CoV-2 rS, 0.5 mL
Pts 15
Age Adult, Older_Adult
Cohort11: prior vaccination with Pfize_HIV infected_BNT162b2
Administration route intramuscular injection
Dosage BNT162b2, 0.3 mL
Pts 85
Age Adult, Older_Adult
Cohort12: prior vaccination with Pfize_HV_BNT162b2
Administration route intramuscular injection
Dosage BNT162b2, 0.3 mL
Pts 15
Age Adult, Older_Adult
Cohort13: no prior COVID-19 vaccination_HIV infected_Ad26.COV2.S
Administration route intramuscular injection
Dosage Ad26.COV2.S, 0.5 mL
Pts 50
Age Adult, Older_Adult
Cohort14: no prior COVID-19 vaccination_HIV infected_SARS-CoV-2 rS
Administration route intramuscular injection
Dosage SARS-CoV-2 rS, 0.5 mL
Pts 50
Age Adult, Older_Adult
Cohort15: no prior COVID-19 vaccination_HIV infected_BNT162b2
Administration route intramuscular injection
Dosage BNT162b2, 0.3 mL
Pts 50
Age Adult, Older_Adult

Relationship Graph

Overview of Knowledge Graph